Expert Interviews

Experts discuss tailored approaches to neoadjuvant therapy for esophageal and G-junction cancers, emphasizing the importance of multidisciplinary care.

Explore the evolving landscape of cancer treatment strategies, focusing on guideline-based management and the impact of multimodal approaches on patient outcomes.

Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.

Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.

Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.

Demonstrates that longer amivantamab exposure further reduces the emergence of MET and EGFR mutations.

Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.

The experts conclude this program by discussing future biomarker-guided approaches in bladder cancer treatment.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

Misako Nagasaka, MD, PhD, summarizes the key takeaways: proactive AE management, CNS vigilance, and strategic sequencing as hallmarks of modern care for EGFR-mutant NSCLC.

Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.

The discussion underscores the role of multidisciplinary coordination in maintaining adherence, quality of life, and long-term therapeutic benefit.

Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.

Findings from numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the past several years.

Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.

A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.

Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.

Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.

Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.

Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.